Qiagen NV (XTER:QIA) Research & Development: €165 Mil (TTM As of Mar. 2026)


XTER:QIA Qiagen NV XTER:QIA
71 GF Score
Price €34.57
GF Value €45.80
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Qiagen NV Research & Development?

Qiagen NV XTER:QIA +0.74% 71 Research & Development is €165 Mil as of Mar. 2026. GuruFocus rates XTER:QIA with a GF Score™ of 71/100 and a GF Value™ of €45.80 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Qiagen NV's Research & Development for the three months ended in Mar. 2026 was €42 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €165 Mil.

Qiagen NV  (XTER:QIA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Qiagen NV Research & Development Related Terms

Qiagen NV Research & Development Historical Data

* Premium members only.

The historical data trend for Qiagen NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV Research & Development Chart

Qiagen NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 168.12 179.23 182.04 184.79 160.14

Qiagen NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.50 41.40 41.53 40.34 41.75
XTER:QIA
71GF Score
Qiagen NV XTER:QIA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qiagen NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €165 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €165 Mil mean?
Qiagen NV (XTER:QIA) has a Research & Development of €165 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Qiagen NV and its competitors.
Is Qiagen NV's Research & Development too high?
Qiagen NV's current Research & Development is €165 Mil. Overall, Qiagen NV has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Research & Development compare to TWST and CRL?
Qiagen NV's Research & Development of €165 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Qiagen NV and its competitors. Qiagen NV's current Research & Development is €165 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.80, compared to a current price of €34.57 — trading 24.5% below its estimated fair value. The current Research & Development is €165 Mil. Qiagen NV's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Research & Development is €165 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qiagen NV (XTER:QIA) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €34.57 is trading 24.5% below its estimated GF Value™ of €45.80. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for XTER:QIA:

  • Research & Development: €165 Mil
  • GF Value™: €45.80 vs. price of €34.57 (24.5% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
71GF Score

Get the complete analysis for XTER:QIA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.57
Price
€45.80
GF Value